Publications by authors named "D A Regier"

Introduction: Genomic medicine has features that make it preference sensitive and amenable to model-based health economic evaluation. Preferences of patients, caregivers, and clinicians related to the uptake and delivery of genomic medicine technologies and services that are not captured in health state utility weights can affect the intervention's cost-effectiveness and budget impact. However, there is currently no established or agreed-on approach for integrating preference information into economic evaluations.

View Article and Find Full Text PDF

Trifunctional protein deficiency (TFP) is a disorder of fatty acid beta-oxidation associated with metabolic, cardiac, and liver dysfunction in severe forms. We present two siblings diagnosed by newborn screening and confirmed by biochemical testing at birth. Their clinical course was complicated by recurrent rhabdomyolysis, retinopathy, and hypoparathyroidism.

View Article and Find Full Text PDF

Background: Evaluating precision oncology outcomes requires access to real-world and clinical trial data. Access is based on consent, and consent is based on patients' informed preferences when deciding to share their data. Decision-making is often modeled using utility theory, but a complex decision context calls for a consideration of how heuristic, intuitive thought processes interact with rational utility maximization.

View Article and Find Full Text PDF

Purpose: With increases in precision medicine initiatives and genetically defined rare diseases, the genetics and metabolism workforce is necessary to provide around-the-clock care for patients. Here, we describe the impact that home-based call has on the geneticist and metabolist workforce.

Methods: Physicians from 3 populations were self-identified (pediatric subspecialist, geneticist, metabolist) and completed a survey regarding the impact of home-based call service on their sleep and wellness.

View Article and Find Full Text PDF
Article Synopsis
  • * They used a retrospective design to match patients receiving the multi-gene test to those undergoing single-gene testing, focusing on survival outcomes and costs from a healthcare payer's perspective.
  • * Results showed that multi-gene panel testing had longer turnaround times and slightly increased costs, but it also resulted in marginally better survival rates; however, the overall net monetary benefit was inconclusive, with varying cost-effectiveness results across multiple scenarios.
View Article and Find Full Text PDF